Publications by authors named "Y Birger"

Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.

View Article and Find Full Text PDF

Histiocytoses are inflammatory myeloid neoplasms often driven by somatic activating mutations in mitogen-activated protein kinase (MAPK) cascade genes. H syndrome is an inflammatory genetic disorder caused by germ line loss-of-function mutations in SLC29A3, encoding the lysosomal equilibrative nucleoside transporter 3 (ENT3). Patients with H syndrome are predisposed to develop histiocytosis, yet the mechanism is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • The ERG transcription factor is linked to various cancers, particularly leukemia, but its specific mechanisms and interactions are not well understood.
  • Our research highlights the importance of proline at position 199 in the PNT domain of ERG, which is essential for its role in promoting leukemia by enabling self-renewal and inhibiting myeloid differentiation.
  • We found that proline 199 allows ERG to interact with the NCoR-HDAC3 co-repressor complex, and blocking HDAC3 slows down the growth of cancers driven by ERG, suggesting that targeting this interaction could be a new treatment strategy.
View Article and Find Full Text PDF

Mono-allelic germline disruptions of the transcription factor GATA2 result in a propensity for developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), affecting more than 85% of carriers. How a partial loss of GATA2 functionality enables leukemic transformation years later is unclear. This question has remained unsolved mainly due to the lack of informative models, as Gata2 heterozygote mice do not develop hematologic malignancies.

View Article and Find Full Text PDF

Kinase signaling fuels growth of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Yet its role in leukemia initiation is unclear and has not been shown in primary human hematopoietic cells. We previously described activating mutations in interleukin-7 receptor alpha (IL7RA) in poor-prognosis "ph-like" BCP-ALL.

View Article and Find Full Text PDF